Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase

Journal of Medicinal Chemistry

Volumn 42, Issue 17, 1999, Pages 3356-3368

  Anthony, Neville J ^a   Gomez, Robert P ^a   Schaber, Micheal D ^a   Mosser, Scott D ^a   Hamilton, Kelly A ^a   O'Neil, Timothy J ^a   Koblan, Kenneth S ^a   Graham, Samuel L ^a   Hartman, George D ^a   Shah, Daksha ^a   Rands, Elaine ^a   Kohl, Nancy E ^a   Gibbs, Jackson B ^a   Oliff, Allen I ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; ONCOGENE H RAS; PROTEIN PROCESSING; RAT; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR REGRESSION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TRANSFORMED; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; IMIDAZOLES; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PRODRUGS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13044300878     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990080l     Document Type: Article

References (49)

1. Clark, G. J.; Der, C. J. Ras Proto-Oncogene Activation In Human Malignancy. In Cellular Cancer Markers; Garrett, C. T., Sell, S., Eds.; Humana Press: Totowa, 1995; pp 17-52.
2. Bos, J. L. Ras Oncogenes In Human Cancer. Cancer Res. 1989, 49, 4682-4689.
3. Gibbs, J. B. Ras C-Terminal Processing Enzymes - New Drug Targets. Cell 1991, 65, 1-4.
4. Gibbs, J. B.; Oliff, A. I. The Potential Of Farnesyltransferase Inhibitors As Cancer Chemotherapeutics. Annu. Rep. Biopharmacol. Toxicol. 1997, 37, 143-166.
5. Clarke, S. Protein Isoprenylation And Methylation At Carboxy-Terminal Cysteine Residues. Annu. Rep. Biochem. 1992, 61, 355-386.
6. Moores, S. L.; Schaber, M. D.; Mosser, S. D.; Rands, E.; O'Hara, M. B.; Garsky, V. M.; Marshall, M. S.; Pompliano, D. P.; Gibbs, J. B. Sequence Dependence Of Protein Prenylation. J. Biol. Chem. 1991, 266, 14603-14610.
7. Pompliano, D. L.; Rands, E.; Schaber, M. D.; Mosser, S. D.; Anthony, N. J.; Gibbs, J B. Steady-State Kinetic Mechanism Of Ras Farnesyl: Protein Transferase. Biochemistry 1992, 31, 3800-3807.
8. Pompliano, D. L.; Schaber, M. D.; Mosser, S. D.; Omer, C. A.; Shafer, J. A.; Gibbs, J. B. Isoprenoid Diphosphate Utilization By Recombinant Human Farnesyl: Protein Transferase: Interactive Binding Between Substrates And A Preferred Kinetic Pathyway. Biochemistry 1993, 32, 8341-8347.
9. Furfine, E. S.; Leban, J. J.; Landavazo, A.; Moomaw, J. F.; Casey, P. J. Protein Farnesyltranferase: Kinetics Of Farnesyl Pyrophosphate Binding And Product Release. Biochemistry 1995, 34, 6857-6862.
10. Huang, C.; Casey, P. J.; Fierke, C. A. Evidence For A Catalytic Role Of Zinc In The Protein Farnesyltransferase. J. Biol. Chem. 1997, 272, 20-33
11. Kral, A. M.; Diehl, R. E.; deSolms, S. J.; Williams, T. M.; Kohl, N. E.; Omer, C. A. Mutational Analysis Of Conserved Residues Of The β-Subumt Of Human Farnesyl: Protein Transferase. J. Biol. Chem. 1997, 272, 27319-27323.
12. Mu, Y.; Omer, C. A.; Gibbs, J. A. On The Stereochemical Course Of Human Protein-Farnesyl Transferase. J. Am. Chem. Soc. 1996, 118, 1817-1823.
13. Dolence, J. M.; Poulter, C. D. A Mechanism For Posttranslational Modifications Of Proteins By Yeast Protein Farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 5008-5011.
14. Tschantz, W. R.; Furfine, E. S.; Casey, P. J. Substrate Binding Is Required For Release Of Product From Mammalian Protein Farnesyltransferase. J. Biol. Chem. 1997, 272, 9989-9993.
15. Long, S. B.; Casey, P. J.; Beese, L. S. Cocrystal Structure Of Protein Farnesyltransferase Complexed With A Farnesyl Diphosphate Substrate. Biochemistry 1998, 37, 9612-9618.
16. Dunten, P.; Kammlott, U.; Crowther, D.; Palermo, R.; Birktoft, J. Protein Farnesyltransferase: Structure And Implications For Substrate Binding. Biochemistry 1998, 37, 7907-7912.
17. Graham, S. L. Inhibitors Of Protein Farnesylation: A New Approach To Cancer Chemotherapy. Exp. Opin. Ther. Patents 1995, 5, 1269-1285.
18. Graham, S. L.; Williams, T. M. Inhibitors Of Protein Farnesylation. Exp. Opin. Ther. Patents 1996, 6, 1295-1304.
19. Williams, T. M. Inhibitors Of Protein Farnesylation. Exp. Opin. Ther. Patents 1998, 8, 553-569.
20. James, G L.; Goldstein, J. L.; Brown, M. S.; Rawson, T. E.; Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.; Levinson, A. D.; Masters, J. C. Benzodiazepine Peptidometics: Potent Inhibitors Of Ras Farnesylation In Animal Cells. Science 1993, 37, 7907-7912.
21. Kohl, N. E.; Mosser, S. D.; deSolms, S. J.; Guiliani, S. J.; Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.; Oliff, A.; Gibbs, J. B. Selective Inhibition Of ras-Dependent Transformation By A Farnesyltransferase Inhibitor. Science 1993, 260, 1934-1937.
22. Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Guiliani, E.; deSolms, S. J.; Conner, M. W.; Anthony, N. J., Holtz, W. J.; Gomez, R. P.; Lee, T.; Smith, R. L.; Graham, S. L.; Hartman, G. D.; Gibbs, J. B.; Oliff, A. Protein Farnesyltransferase Inhibitors Block The Growth Of ras-Dependent Tumors In Nude Mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141-9145.
23. Nagasu, T.; Yoshimatsu, K.; Rowell, C.; Lewis, M. D.; Garcia, A. M. Inhibition Of Human Tumor Xenograft Growth By Treatment With The Farnesyltransferase Inhibitor B956. Cancer Res. 1995, 55, 5310-5314.
24. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth In Nude Mice Of A Human Lung Carcinoma With K-Ras Mutation And p53 Deletion. Cancer Res. 1995, 55, 4243-4247.
25. Kohl, N. E.; Omer, C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P.; deSolms, S. J.; Guiliani, E.; Gomez, R. P.; Graham, S. L.; Hamilton, K.; Handt, L. K.; Hartman, G. D; Koblan, K. S.; Kral, A. M.; Miller, P. J.; Mosser, S. D.; O'Niel, T. J.; Rands, E.; Schaber, M. D.; Gibbs, J. B.; Oliff, A. Inhibition Of Farnesyltransferase Induces Regression Of Mammary And Salivary Carcinomas In ras-Transgenic Mice. Nature Med. 1995, 1, 792-797.
26. Lobell, R. B.; Kohl, N. E. Pre-clinical Development of Farnesyltransferase Inhibitors. Cancer Metastasis Rev. 1998, 17, 203-210.
27. Cox, A. D.; Der, C. J. Faresnyltransferase Inhibitors and Cancer Treatment: Targeting Simply Ras. Biochim. Biophys. Acta 1997, 1333, F51-F71.
28. Lebowitz, P. F.; Prendergast, G. C. Non-Ras Targets of Farnesyltransferase Inhibitors: Focus on Rho. Oncogene 1998, 17, 1439-1445.
29. Sepp-Lorenzino, L.; Ma, Z.; Rands, E.; Kohl, N. E.; Gibbs, J. B.; Oliff, A.; Rosen, A. A Peptidomimetic Inhibitor of Farnesyl: Protein Transferase Blocks the Anchorage-dependent And -independent Growth of Human Tumor Cell Lines. Cancer Res. 1995, 55, 5302-5309.
30. Du, W.; Lebowitz, P. F.; Prendergast, G. C. Elevation of α2(I) Collagen, A Suppressor of Ras Transformation, Is Required for Stable Phenotypic Reversion by Farnesyltransferase Inhibitors. Cancer Res. 1999, 59, 2059-2063.
31. deSolms, S. J.; Guiliani, E. A.; Graham, S. L.; Koblan, K. S.; Kohl, N E.; Mosser, S. D.; Oliff, A.; Pompliano, D. L.; Rands, E.; Scholz, T. H.; Wiscount, C. M.; Gibbs, J. B.; Smith, R. L. N-Arylalkyl Pseudopeptide Inhibitors Of Farnesyltransferase. J. Med. Chem. 1998, 41, 2651-2656.
32. deSolms, S. J. Unpublished Results.
33. Breslin, M. J.; deSolms, S. J.; Guiliani, E. A.; Stokker, G. E.; Graham, S. L.; Pompliano, D. L.; Mosser, S. D.; Hamilton, K. A.; Hutchinson, J. H. Potent, Non-Thiol Inhibitors Of Farnesyltransferase. Bioorg. Med. Chem. Lett. 1998, 8, 3311-3316.
34. 2X Motif. Bioorg. Med. Chem. Lett. 1994, 4, 887-892.
35. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
36. Leonard, D. M.; Shuler, K. R.; Poulter, C. J.; Eaton, S. R.; Sawyer, T. K.; Hodges, J. C.; Su, T.-Z.; Scholten, J. D.; Gowan, R. C.; Sebolt-Leopold, J. S.; Doherty, A. M. Structure Activity Relationships Of Cysteine-Lacking Pentapeptide Derivatives That Inhibit ras Farnesyltransferase. J. Med. Chem. 1997, 40, 192-200.
37. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Rithofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification Of Novel Farnesyl Protein Transferase Inhibitors Using Three-Dimensional Database Searching Methods. J. Med. Chem. 1997, 40, 4103-4112.
38. McNamara, D. J.; Dobrusin, E.; Leonard, D. M.; Shuler, K. R.; Kaltenbronn, J. S.; Quin, J.; Bur, S.; Thomas, C. E.; Doherty, A. M.; Scholten, J. D.; Zimmerman, K. K.; Gibbs, B. S.; Gowan, R. C.; Latash, M. P.; Leopold, W. R.; Przybranowski, S. A.; Sebolt-Leopold, J. S. C-Terminal Modifications Of Histidyl-N-benzylglycinamides To Give Improved Inhibition Of Ras Farnesyltransferase, Cellular Activity and Anticancer Activity in Mice. J. Med. Chem. 1997, 40, 3319-3322.
39. Shen, W.; Fakhourly, S.; Donner, G.; Henry, K.; Lee, J.; Zhang, H.; Cohen, J.; Warner, R.; Saeed, B.; Cherian, S.; Tahir, S.; Kovar, P ; Bauch, J.; Ng, S.-C.; Marsh, K.; Sham, H.; Rosenberg, S. Potent Inhibitors of Protein Farnesyltransferase: Heteroarenes As Cysteine Replacements. Bioorg. Med. Chem. Lett. 1999, 9, 703-708.
40. Jones, J. H.; Rathbone, D. L.; Wyatt, P. B. The Regiospecific Alkylation Of Histidine Side Chains. Synthesis 1987, 1110-1113.
41. Hodges, J. C. Regiospecific Synthesis Of 3-Substituted L-Histidines. Synthesis 1987, 1, 20-24.
42. The unoptimized yields for the alkylation reactions were in the range of 45-85%.
43. Patel, D. V. Phosphinyl Acid Based Bisubstrate Analogue Inhibitors Of Ras Farnesyl Protein Transferase. J. Am. Chem. Soc. 1995, 38, 435-442.
44. 5.
45. This topic will be the subject of future reports from these laboratories.
46. Smith, M. R.; DeGrubicibus, S. J.; Stacey, D. W. Requirement For c-ras Proteins During Viral Oncogene Transformation. Nature 1986, 320, 540-543.
47. Prendegast, G. C.; Davide, J. P.; deSolms, S. J.; Guiliani, E.; Graham, S. L.; Gibbs, J. B.; Oliff, A.; Kohl, N. E. Farnesyltransferase Inhibition Causes Morphological Reversion Of RasTransformed Cells By A Complex Mechanism That Involves Regulation Of The Actin Cytoskeleton. Mol. Cell B 1994, 14, 4193-4202.
48. Experiments conducted in rodents have revealed that the methyl ester prodrug 20 is very rapidly hydrolyzed (<1 min) in nude mice or rat following iv administration and that approximately 90% of the iv dose of 20 is excreted in the bile as the corresponding acid 21. Despite this rapid hydrolysis, iv administration of the prodrug 20 to rats (4 mpk) resulted in 2-6-fold greater concentrations of the active acid 21 in heart, lung, and spleen tissues (5 min postdosing) than dosing the acid 21. In these experiments very little parent ester 20 was observed in the tissues. These results indicate that the prodrug ester 20 is more tissue penetrant than the acid 21 and that the acid is additionally subject to efficient biliary excretion.
49. This dose was selected based upon pharmacodynamic data: sc dosing of the ester 20 (40 mpk) to nude mice resulted in relatively constant drug levels in both the plasma (1-2 μM) and tissues (spleen 0.4-1 μM) for a period of 6 h. These drug concentrations were sufficient to significantly (>90%) inhibit the farnesyltransferase activity present in cytosolic fractions of homogenized spleen tissue derived from drug-treated animals verses non-drug-treated control animals.